Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | FRK | P42685 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.52 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744194 | 0.92 | PTGS2 (0.56) | PTGS2CYP11B2CYP11B1TNFPRKD3 | |
| SCHEMBL30023075 | 0.89 | MAPK14 (0.57) | PTGS2CYP11B2CYP11B1TNFMAP4K4 | |
| Bromide SCHEMBL30023275 | 0.88 | MAPK14 (0.56) | PTGS2CYP11B2CYP11B1MAP4K4MAPK9 | |
| Hydrochloric Acid SCHEMBL30023189 | 0.88 | MAPK14 (0.56) | PTGS2CYP11B2CYP11B1MAP4K4MAPK9 | |
| SCHEMBL10993362 | 0.85 | PTGS2 (0.64) | PTGS2CYP11B2CYP11B1TP53LMNA | |
| SCHEMBL8480092 | 0.81 | PTGS2 (0.59) | PTGS2PRKD3MAP4K4FRKMAPK9 | |
| SCHEMBL4805174 | 0.80 | PTGS2 (0.63) | PTGS2PRKD3MAP4K4FRKMAPK9 | |
| SCHEMBL11424185 | 0.79 | PTGS2 (0.54) | PTGS2PRKD3MAP4K4FRKMAPK9 | |
| SCHEMBL27934319 | 0.78 | PTGS2 (0.55) | PTGS2CYP11B2CYP11B1TP53LMNA | |
| SCHEMBL27915572 | 0.78 | PTGS2 (0.55) | PTGS2CYP11B2CYP11B1TP53MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139574-B2 | Tumor targeted drug combretastatin A4 derivative | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| WO-1992017470-A1 | IMIDAZOLES | RHONE-POULENC RORER LIMITED (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0506437-A1 | Imidazoles | RHONE POULENC RORER LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
| US-5102900-A | Antilipemic and anticholesterol agents | RHONE-POULENC RORER S.A. (FR) | 1992-04-07 | — | — | US | disclosed |
| WO-1992005148-A1 | IMIDAZOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS | RHONE-POULENC RORER LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| EP-0424195-A1 | Imidazoles | RHONE-POULENC SANTE (FR) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128384-A1 | TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE | TUBA4A, TUBGCP4, TUBB4A | PTGS2 4150/4885CYP11B2 3908/4885CYP11B1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.